| DC73146 |
MK-1468
|
MK-1468 is a potent, selective, brain-penetrant LRRK2 inhibitor with IC50 of 0.4 nM (G2019S LRRK2), potently inhibits the phosphorylation of LRRK2 serine 935 (pSer935) in hPBMCs with IC50 of 2.8 nM. |
| DC73145 |
FX2149
|
FX2149 (FX 2149) is a potent, BBB permeable inhibitor of LRRK2 GTP binding activity with IC90 of 10 nM, reduces PD-linked mutant LRRK2 variants (G2019S and R1441C) that bound with GTP. |
| DC72873 |
MTK458
|
MTK458 (MTK-458) is a potent, selective and brain penetrant PINK1 activator, MTK-458 promotes the first step in mitophagy.
MTK458 selectively activates PINK1 by stimulating dimerization and stabilization of the PINK1/TOM complex.
MTK458 binds to PINK1 and stabilizes an active heterocomplex, thereby increasing mitophagy.
MTK458 reduces the PINK1 substrate pS65-Ubiquitin (pUb) in primary neurons and in vivo.
MTK458 drives clearance of pathologic α-synuclein in vitro and in vivo, decreases pS129 α-synuclein aggregates and normalized both brain and corresponding plasma pUb levels in both cellular and animal models of α-synuclein aggregation (PD-like pathology). |
| DC72558 |
GLPG3970
|
GLPG3970 (compound 88) is a first-in-class SIK2/SIK3 inhibitor. GLPG3970 can be used for the research of inflammation and autoimmune disease. |
| DC70343 |
DCC-3116
|
DCC-3116 (DCC3116) is a first-in-class, selective inhibitor of ULK1/2 kinases (IC50=4.7/35 nM) and autophagy.DCC-3116 is an oral ULK1/2 inhibitor targeting the autophagy pathway, a key mechanism of tumor survival and resistance to targeted therapy. |
| DC48117 |
EB-42486
|
EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50 < 0.2 nM). |
| DC46639 |
WH-4-025
|
WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2). |
| DC28954 |
Curcumin analog C1(TFEB activator 1 )
|
TFEB activator 1 is an orally effective, mTOR-independent activator of TFEB. TFEB activator 1 significantly promotes the nuclear translocation of Flag-TFEB with an EC50 of 2167 nM. TFEB activator 1 enhances autophagy without inhibiting the mTOR pathway an |
| DC10635 |
MRT67307 HCl
|
MRT67307 is a potent and dual IKKϵ and TBK1 inhibitor with IC50 of 160 and 19 nM, respectively. |
| DC10360 |
MLi-2
|
MLi-2 is an a potent, highly selective, orally available, brain penetrant inhibitor of LRRK2 with an IC50 of 0.76 nM. |
